A Phase 2 interventional study of Capecitabine and Cisplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 24 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-09.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Stomach Neoplasms by Hoffmann-La Roche — none open to participants now, 2 under way, none of them phase 3. Stomach Neoplasms · Hoffmann-La Roche.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 20th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 2, and was the 9th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →None of the 29 studies in Stomach Neoplasms by Hoffmann-La Roche is open now. The open studies under Stomach Neoplasms, anywhere →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 8 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 158 across the 23 interventional studies, 503 across the 6 observational. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, multicenter, open-label study will evaluate two different doses of pertuzumab in combination with Herceptin (trastuzumab) and chemotherapy in the first-line treatment of participants with metastatic HER2-positive adenocarcinoma of the stomach or gastroesophageal junction. Participants will be randomized in a 1:1 ratio to two treatment arms. Participants in the Pertuzumab 840/420 mg Arm will receive a pertuzumab loading dose of 840 mg for Cycle 1 and a dose of 420 mg for Cycles 2-6, and participants in the Pertuzumab 840/840 mg Arm will receive pertuzumab 840 mg for all six cycles. Participants in both treatment arms will receive trastuzumab, cisplatin, and capecitabine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m\^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
Drug: Capecitabine · Drug: Cisplatin · Drug: Pertuzumab · Drug: Trastuzumab
Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m\^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
Drug: Capecitabine · Drug: Cisplatin · Drug: Pertuzumab · Drug: Trastuzumab
1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
Also known as: Xeloda
80 mg/m2 on Day 1 of each cycle
loading dose of 840 mg, then 420 mg once every three weeks
Also known as: Perjeta
840 mg once every three weeks
Also known as: Perjeta
loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
Also known as: Herceptin
Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL)
Time frame: Day 43
Number of Participants With Adverse Events (AEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.
Time frame: From randomization of first participant to end of study (approximately 6 years)
| Milestone | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg |
|---|---|---|
| Started | 15 | 15 |
| Completed | 0 | 0 |
| Not completed | 15 | 15 |
| Withdrew: Death | 10 | 9 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Progression of disease | 1 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 0 |
| percentage of participants | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg |
|---|---|---|
| Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL) | 91.6 (78.3 to 99.2) | 98.3 (91.4 to 99.97) |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.
| participants | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 15 | 15 |
Collected over From randomization of first participant to end of study (approximately 6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab 840/420 mg | 10/15 (66.7%) | 11/15 (73.3%) | 15/15 (100%) |
| Pertuzumab 840/840 mg | 9/15 (60%) | 10/15 (66.7%) | 15/15 (100%) |
| Event | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/15 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 2/15 | 3/15 |
| VomitingGastrointestinal disorders | 2/15 | 0/15 |
| AstheniaGeneral disorders | 2/15 | 0/15 |
| Mucosal inflammationGeneral disorders | 2/15 | 0/15 |
| Neutrophil count decreasedInvestigations | 2/15 | 0/15 |
| HyponatraemiaMetabolism and nutrition disorders | 2/15 | 0/15 |
| Cardiac failure acuteCardiac disorders | 1/15 | 0/15 |
| AscitesGastrointestinal disorders | 1/15 | 0/15 |
| DyspepsiaGastrointestinal disorders | 0/15 | 1/15 |
| Event | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/15 | 11/15 |
| NauseaGastrointestinal disorders | 11/15 | 13/15 |
| AnaemiaBlood and lymphatic system disorders | 9/15 | 11/15 |
| Neutrophil count decreasedInvestigations | 11/15 | 11/15 |
| Decreased appetiteMetabolism and nutrition disorders | 11/15 | 9/15 |
| StomatitsGastrointestinal disorders | 9/15 | 6/15 |
| VomitingGastrointestinal disorders | 9/15 | 3/15 |
| HypomagnesaemiaMetabolism and nutrition disorders | 8/15 | 3/15 |
| DizzinessNervous system disorders | 8/15 | 3/15 |
| FatigueGeneral disorders | 5/15 | 7/15 |
| Age, Customized(Participants) | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg | Total |
|---|---|---|---|
| 18 - 40 years | 2 | 1 | 3 |
| 41 - 64 years | 4 | 9 | 13 |
| Greater than or equal to (>=) 65 years | 9 | 5 | 14 |
| Sex: Female, Male(Participants) | Pertuzumab 840/420 mg | Pertuzumab 840/840 mg | Total |
|---|---|---|---|
| Female | 1 | 5 | 6 |
| Male | 14 | 10 | 24 |
Ran from Dec 2011 to primary completion in Mar 2015, 38 months.
Results were first posted in Jun 2016, 1 year 3 months after primary completion.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 38 months is close to that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab